A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV

被引：0
|
作者：
Morlock, Robert
Yu, Elaine
Ray, Joshua
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Genentech Inc, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
417
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [2] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 250 - 251
  • [3] Safety and effectiveness of bevacizumab (BV) plus chemotherapy (CT) in elderly patients with mCRC: results from the BRiTE registry
    Sugrue, M.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Purdie, D.
    Yi, J.
    Grothey, A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 250 - 250
  • [4] Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)
    Bekaii-Saab, T. S.
    Bendell, J. C.
    Cohn, A. L.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Observational cohort study focused on treatment continuity of patients (pts) treated with XELOX plus bevacizumab (BV) for previously untreated metastatic colorectal cancer (mCRC).
    Kotaka, Masahito
    Ikeda, Husao
    Ikumoto, Taro
    Tsuzie, Masaki
    Yoshioka, Shinichi
    Nakamoto, Yoshihiko
    Ishii, Takaaki
    Goto, Saori
    Itami, Atsushi
    Kato, Takeshi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (MCRC): Results from the BRiTE observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Purdie, D.
    Berlin, J.
    Flynn, P.
    Kabbinavar, F.
    Sargent, D.
    Dong, W.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [7] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study
    Kozloff, M. F.
    Sugrue, M. M.
    Purdie, D. M.
    Berlin, J. D.
    Flynn, P. J.
    Kabbinavar, F. F.
    Sargent, D. J.
    Dong, W.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Safety and effectiveness of bevacizumas (BV) plus chemotherapy (CT) in elderly patients with MCRC: Results from the brite registry
    Sugrue, M.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII87 - VII87
  • [10] Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer
    Li, Yulian
    Hu, Min
    Zhang, Zhe
    Chu, Mingming
    Xu, Rufu
    Liu, Lulu
    Dong, Wenxing
    Yang, Mengmeng
    Zhang, Rong
    [J]. CANCER MEDICINE, 2024, 13 (01):
12345